Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders

Authors

  • Mark Forrest Gordon,

    1. Department of Neurology, The Neurological Institute, Columbia-Presbyterian Medical Center, New York, New York, U.S.A
    Search for more papers by this author
  • Rolando Diaz-Olivo,

    1. Department of Neurology, The Neurological Institute, Columbia-Presbyterian Medical Center, New York, New York, U.S.A
    Search for more papers by this author
  • Ann L. Hunt,

    1. Department of Neurology, The Neurological Institute, Columbia-Presbyterian Medical Center, New York, New York, U.S.A
    Search for more papers by this author
  • Dr. Stanley Fahn

    Corresponding author
    1. Department of Neurology, The Neurological Institute, Columbia-Presbyterian Medical Center, New York, New York, U.S.A
    • Neurological Institute, 710 West 168th Street, New York, NY 10032-3784, U.S.A
    Search for more papers by this author

Abstract

We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/ day, orally, and increased gradually to a maximum of 4,800 mg/ day. No clear-cut observable improvement occurred. There were no serious adverse effects.

Ancillary